The FDA's approval of vepdegestrant marks a groundbreaking shift in cancer therapy by introducing PROTAC technology for advanced breast cancer treatment.
Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant ...
A new review examines how advances in drug design, PROTAC degraders and combination therapies are reviving the clinical ...
PROTACs have helped redefine what may be possible in drug discovery. By harnessing the ubiquitin-proteasome system to ...
A study published in Oncogene presents an innovative strategy for the particularly complex medical challenge of destroying aggressive, treatment-resistant tumors. The research was jointly led by early ...
BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, ...
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in ...
Edifier International, the award-winning audio electronics designer, announces the launch of its latest studio monitor, the MR4.5. Whether you're producing music, editing content, or simply enjoying ...
Self-propelled nanoparticles use tumor cell chemistry to find target proteins more efficiently and trigger their removal.
Design of targeted protein degraders is more than target degradation. Linker architecture, molecular flexibility, solubility, permeability, synthesis, purification, and formulation can all influence ...
According to MarketsandMarketstm, the ballistic protection market is projected to grow from USD 12.60 billion in 2026 to USD 16.29 billion by 2031, at a CAGR of 5.3%. Browse 200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results